AVEO Oncology announces clinical updates to tivozanib and ficlatuzumab programs
AVEO Oncology announced clinical updates for FOTIVDA® (tivozanib), the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor receptors, and ficlatuzumab, the Company’s humanized IgG1 antibody that binds to the HGF ligand. December 07, 2017